BNP Paribas Arbitrage SA boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 69.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,060 shares of the company’s stock after acquiring an additional 4,947 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Omnicell were worth $520,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of OMCL. Ameritas Investment Partners Inc. acquired a new stake in Omnicell during the first quarter worth $125,000. LS Investment Advisors LLC increased its stake in Omnicell by 136.3% during the first quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock worth $145,000 after acquiring an additional 2,060 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Omnicell during the first quarter worth $170,000. Sei Investments Co. increased its stake in Omnicell by 36.4% during the second quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock worth $200,000 after acquiring an additional 1,242 shares during the last quarter. Finally, Miles Capital Inc. acquired a new stake in Omnicell during the first quarter worth $231,000. 96.35% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Omnicell, Inc. (OMCL) Holdings Raised by BNP Paribas Arbitrage SA” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/14/omnicell-inc-omcl-holdings-raised-by-bnp-paribas-arbitrage-sa.html.

In other news, Chairman Randall A. Lipps sold 40,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $49.76, for a total transaction of $1,990,400.00. Following the completion of the sale, the chairman now directly owns 196,551 shares in the company, valued at approximately $9,780,377.76. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Randall A. Lipps sold 31,527 shares of the company’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $42.87, for a total value of $1,351,562.49. Following the sale, the chairman now owns 196,551 shares of the company’s stock, valued at $8,426,141.37. The disclosure for this sale can be found here. Insiders sold a total of 202,309 shares of company stock valued at $9,787,437 over the last quarter. 3.77% of the stock is currently owned by insiders.

Omnicell, Inc. (NASDAQ:OMCL) opened at 50.10 on Thursday. The stock’s 50 day moving average price is $49.53 and its 200 day moving average price is $43.24. The stock’s market capitalization is $1.88 billion. Omnicell, Inc. has a 52-week low of $30.35 and a 52-week high of $52.70.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. The company had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. Omnicell’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.38 EPS. On average, analysts forecast that Omnicell, Inc. will post $1.30 EPS for the current year.

OMCL has been the subject of several recent analyst reports. Dougherty & Co raised their target price on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Craig Hallum raised their target price on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Cantor Fitzgerald reissued a “buy” rating and set a $47.00 target price on shares of Omnicell in a research note on Tuesday, July 25th. Benchmark Co. raised their target price on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. Finally, BidaskClub cut Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Omnicell has a consensus rating of “Buy” and a consensus target price of $51.57.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.